Table of Contents For This Page
Report to the Nation - 2004
Perspectives on Prostate Cancer Diagnosis and Treatment: A Roundtable
Transdermal Estradiol therapy
Androgen Deprivation Therapy for Prostate Cancer
Prostate Cancer: Metastatic and Advanced Disease
Report to the Nation - 2004
Prostate cancer is a high-profile disease due to its high incidence, the large number of men dying yearly from the disease, the considerable controversy surrounding the benefit and risks of early detection, and the fact that no consensus exists for the management of many stages of this disease. In this Report to the Nation on Prostate Cancer, we have coordinated the efforts of 22 leading experts in prostate cancer treatment and research from diverse backgrounds, subspecialties, and institutions to address the major therapeutic issues in the management of the disease. Within each chapter, the authors present not only a summary of what is currently known, but also a reminder of how much remains to be explored. Click "here" to read the document.
^Top Of Page^
Perspectives on Prostate Cancer Diagnosis and Treatment: A Roundtable
This is a report in the form of a PDF file that had some of the best docs in the country debating PSA testing and Hormonal Therapy. For any that are considering hormonal therapy this is a must read. The wrap up is by Dr. Messing who has a well known study on hormonal therapy. His study is in this section. To download the file click on: Perspectives on Prostate Cancer
^Top Of Page^
Transdermal Estradiol therapy
This is a collection of abstracts about estrogen use in the treatment of prostate cancer as a substitute for Lupron/Zoladex. Actually it is a gathering of some abstracts that are not directly related to prostate cancer but is of interest in terms of results and side effects. To view the abstracts click on TRANSDERMAL ESTRADIOL – ESTROGEN – ABSTRACTS
^Top Of Page^
Androgen Deprivation Therapy for Prostate Cancer
Improved efforts at diagnosing patients with prostate cancer earlier in the disease process have resulted in more patients presenting with curable disease. Primary treatment with radical prostatectomy or radiotherapy in patients with organ-confined prostate cancer demonstrates overall 10-year survival rates of over 75%.[1,2] However, it is estimated that approximately 14% of patients present with locally advanced or metastatic disease, and approximately 40% of patients will relapse after definitive local therapy.[3,4] In these patients, the use of additional therapies to improve outcomes and slow disease progression becomes necessary,[5] and the need for a multidisciplinary approach to evaluate the available options becomes paramount. Click "here" to read the document. You can print the document here. NOTE: The document starts near the bottom of the page.
^Top Of Page^
Prostate Cancer: Metastatic and Advanced Disease
Prostate cancer is the second leading cause of death in the United States in men dying from cancer and is the most commonly diagnosed cancer in American males. Most of the deaths from prostate cancer are related to advanced disease. Continuous advances have provided a new understanding of the diagnosis, staging, and treatment of metastatic and advanced prostate cancer. The earlier definition of advanced disease, in which patients presented with bone metastasis and soft-tissue involvement, has been improved in recent years. Click "here" to access the article.
You must have the Acrobat Reader installed before you can download the PDF files. To download and read PDF files on your computer you must first download the The Acrobat Reader by clicking "here"
^Top Of Page^
| 
Erectile Dysfunction
Brachytherapy / Seed Implants
Hormonal Ablation Treatment
Radiation External - All Kinds
Surgical Removal - All Kinds
Watchful Waiting
Other Conventional Treatments
